Review
Immunology
Ningyue Sun, Yangzi Tian, Yuhan Chen, Weinan Guo, Chunying Li
Summary: Melanoma is a lethal type of skin cancer that is characterized by disordered metabolism. Metabolic rewiring in melanoma not only affects tumor cell behaviors but also interferes with antitumor immunity by influencing the functions of surrounding immune cells. This review summarizes the epidemiology, clinical characteristics, and treatment proceedings of melanoma, as well as the roles of immune cells and metabolic rewiring in tumor immunology.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Goran Micevic, Andrew Daniels, Karine Flem-Karlsen, Koonam Park, Ronan Talty, Meaghan McGeary, Haris Mirza, Holly N. Blackburn, Esen Sefik, Julie F. Cheung, Noah I. Hornick, Lilach Aizenbud, Nikhil S. Joshi, Harriet Kluger, Akiko Iwasaki, Marcus W. Bosenberg, Richard A. Flavell
Summary: This study identifies a specific immune cell population with high IL-7R expression that plays a critical role in antitumor memory and can be enhanced through epigenetics to generate powerful antitumor immune responses. These findings have significant implications for preventing melanoma recurrence and developing new treatment options.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Veterinary Sciences
Tatiany L. Silveira, Lisa Y. Pang, Alexandra Di Domenico, Emerson S. Veloso, Istefani L. D. Silva, Helen L. Del Puerto, Enio Ferreria, David J. Argyle
Summary: Metastatic melanoma is an aggressive form of cancer in humans and dogs, with COX-2 potentially playing a critical role in malignant behavior. The study on canine melanomas showed that COX-2 is overexpressed in both oral and cutaneous melanomas, correlating with poor prognosis markers. The research also established a direct relationship between COX-2 expression and malignant behavior in canine melanoma, providing a powerful molecular tool for further understanding melanoma progression.
FRONTIERS IN VETERINARY SCIENCE
(2021)
Review
Pharmacology & Pharmacy
Juan Tang, Youling Gong, Xuelei Ma
Summary: The discovery of oncogenes and immune checkpoints has revolutionized the treatment of melanoma in the past 10 years. However, the current PD-L1 checkpoints lack specificity for tumors and target normal cells expressing PD-L1, thus reducing the efficacy on malignant melanoma and increasing the side effects. In addition, the treatment options for primary or secondary drug-resistant melanoma are limited. Bispecific antibodies bind tumor cells and immune cells by simultaneously targeting two antigens, enhancing the anti-tumor targeting effect and cytotoxicity and reducing drug-resistance in malignant melanoma, thus representing an emerging strategy to improve the clinical efficacy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
[Anonymous]
Summary: Tumor immunology and cancer immunotherapy is a rapidly evolving field that has seen the implementation of various immunotherapies across different tumor types in the past decade. Novel strategies to overcome resistance and address the tumor microenvironment are currently the focus of research in this area. The Spanish Group for Cancer Immuno-Biotherapies (GeTICA) recently organized the IX Forum on Translational Immunology and Cancer Immunotherapy (FITCancer 9) in Madrid, which is the largest meeting dedicated to cancer immunotherapy and brings together clinicians, researchers, and experts in the field. This article presents abstracts from GeTICA members submitted to the forum.
Article
Immunology
Matias Tellado, Mariangela De Robertis, Daniela Montagna, Daniela Giovannini, Sergio Salgado, Sebastian Michinski, Emanuela Signori, Felipe Maglietti
Summary: This retrospective cohort study evaluated the addition of canine IL-2 gene electrotransfer (GET) peritumorally and IL-12 intramuscularly in inoperable canine oral malignant melanoma. The results showed that ECT+GET using IL-2 and IL-12 significantly improved progression-free survival in advanced stages of canine oral malignant melanoma.
Article
Veterinary Sciences
Lidia Tarone, Davide Giacobino, Mariateresa Camerino, Soldano Ferrone, Paolo Buracco, Federica Cavallo, Federica Riccardo
Summary: Canine melanoma remains a fatal disease, and immunotherapy may offer new treatment approaches. By studying tumor immunology and developing therapies such as anti-cancer vaccines, progress in the field of canine melanoma is hopeful.
FRONTIERS IN VETERINARY SCIENCE
(2022)
Article
Oncology
Jacky Yeung, Vesal Yaghoobi, Danielle Miyagishima, Matthew D. Vesely, Tianxiang Zhang, Ti Badri, Ala Nassar, Xue Han, Miguel F. Sanmamed, Mark Youngblood, Matthieu Peyre, Michel Kalamarides, David L. Rimm, Murat Gunel, Lieping Chen
Summary: Malignant meningiomas are enriched with immunosuppressive myeloid cells. Treatment with anti-CSF1/CSF1R antibodies may be an effective normalization cancer immunotherapy for malignant meningiomas.
Article
Oncology
Gesche Frohwitter, Marie Kerta, Christoph Vogl, Carol Immanuel Geppert, Jan-Erik Werry, Jutta Ries, Marco Kesting, Manuel Weber
Summary: Non-melanoma skin cancer is a heterogeneous tumor entity in which the immune activity plays an important role. By conducting a whole slide analysis of basal cell carcinoma and cutaneous squamous cell carcinoma samples, it was found that there are significant differences in the infiltration of CD8(+) T cells and CD68(+) macrophages between the two cancer types, indicating that cutaneous squamous cell carcinoma is more immunogenic. These findings are important for explaining the differences between the two tumor entities and for the application of immune therapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Zihan Deng, Lisen Lu, Binghui Li, Xiujuan Shi, Honglin Jin, Weidong Hu
Summary: Inflammation is a critical feature in all stages of tumor development. Inflammasomes, as an important component of the inflammatory response and innate immune system, regulate infiltrating immune cell activity by signaling the secretion of different cytokines and chemokines. The expression patterns of inflammasomes vary across tumor types and stages, and understanding their specific effects is crucial for developing inflammasome-targeting drugs.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Nicolas Aide, Amir Iravani, Kevin Prigent, Diane Kottler, Ramin Alipour, Rodney J. Hicks
Summary: F-18-FDG PET/CT is increasingly important in the staging and post-treatment monitoring of high-risk melanoma patients. Technological advances have improved its diagnostic performance in detecting smaller cancer lesions. This article provides advice on melanoma-related PET protocols and emphasizes the recognition of non-malignant diseases and treatment-related findings.
Review
Oncology
Youhuai Li, Mina Wang, Xueqiang Peng, Yingying Yang, Qishuang Chen, Jiaxing Liu, Qing She, Jichao Tan, Chuyuan Lou, Zehuan Liao, Xuexin Li
Summary: Messenger ribonucleic acid (mRNA) vaccines are a promising therapy for infectious diseases and cancer, particularly in the case of SARS-CoV2. Compared to conventional cancer vaccines, mRNA vaccines have advantages such as efficient immune response production, low side effects, and lower acquisition cost. This review discusses the development of cancer vaccines, mRNA cancer vaccines, their potential biological mechanisms, recent progress in tumor treatments, and future challenges and directions in the field.
CLINICAL AND TRANSLATIONAL MEDICINE
(2023)
Review
Cell Biology
Guilhem Lalle, Julie Twardowski, Yenkel Grinberg-Bleyer
Summary: NF-kappa B plays a crucial role in immune responses to cancer and could be targeted by novel immunotherapies.
Article
Oncology
Katelyn F. Handley, Sumit Mehta, Alexandra L. Martin, Subir Biswas, Kamira Maharaj, Mate Z. Nagy, Jessica A. Mine, Carla Cortina, Xiaoqing Yu, Kimberly Sprenger, Gunjan Mandal, Patrick Innamarato, John J. Powers, Carly M. Harro, Ricardo A. Chaurio, Carmen M. Anadon, Mian M. Shahzad, Idhaliz Flores, Jose R. Conejo-Garcia
Summary: The study demonstrates that shared antibody responses in endometriosis and endometriosis-associated ovarian cancer can counteract malignant progression and have the potential for developing immunotherapies. Antibodies targeting tumor-promoting syndecan binding protein (SDCBP) show anti-tumor activity in mouse models of ovarian carcinoma. These findings suggest that utilizing tumor-derived antibodies may be a promising approach for future immunotherapies.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Fengyun Shen, Lele Sun, Lihua Wang, Rui Peng, Chunhai Fan, Zhuang Liu
Summary: This study reported a novel immune adjuvant that can transdermally deliver chemotherapy drugs into melanoma, induce immunogenic death of tumor cells, and trigger systemic tumor-specific immune responses.
